Further elucidation of the pathogenetic interplay between IL-1β and eicosanoids may contribute to the development of neuroprotective and anti-inflammatory interventions in stroke patients, potentially involving the use of agents such as the IL-1β antagonist anakinra, COX-2 inhibitors, or leukotriene receptor antagonists. This evidence concerns the gene IL1B and Stroke.